Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter.
The drugmaker reported a consolidated net profit of Rs 348 crore for the quarter ended December 31 as against a loss of Rs 351 crore in the comparable quarter last year.
At 11:45 am on February 17, Glenmark Pharma shares were trading 4.2% higher at Rs 1,379 apiece.
Net sales rose 34% to Rs 3,302 crore in the quarter, aided by India sales.
Revenue from its US markets grew 1.4% during the quarter, compared with a 5.5% growth in the previous quarter.
However, the company said it anticipates business growth from the financial year 2026 onward, driven by potential launches in the respiratory and injectable segments.
“We delivered strong and sustained growth this quarter, driven by robust performance across the regions. Our European business continued to perform well, while our branded markets demonstrated resilient growth. Looking ahead, we expect our North America business to gain momentum from FY 26 onwards, supported by our growing respiratory and injectable portfolio,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.
